Advances in Precision Medicine for NSCLC: Expert Guidance for Community Practice

Join us for this live 1-hour, CME/CE/CPE-certified workshop to gain expert insights on how to test for and apply new and emerging predictive biomarkers to guide optimal use of targeted therapies and immunotherapies in the care of your patients with lung cancer. Sign up now!

Agenda

  • Introduction
  • Principles of Molecular Testing in Advanced NSCLC
    • Whom should we test for biomarkers?
    • When do we test?
    • How do we test?
    • Why should we test?
  • New and Emerging Actionable Biomarkers for Targeted Therapies in NSCLC
    • Established: EGFR, ALK, ROS1, BRAF
    • Recent: METex14, RET, NTRK
    • New: EGFR ex20ins, KRAS
    • Emerging: HER2, cMET
  • Biomarkers Predicting Response to Immunotherapy-Based Regimens: PD-L1
  • Moving Biomarker Testing to Early-Stage NSCLC
  • Audience Question and Answer Session

Events

Date / Time
Event Details

Faculty

Co-Chair
Zofia Piotrowska, MD, MHS

Assistant Professor
Harvard Medical School
Attending Physician
Division of Hematology/Oncology
Department of Medicine
Massachusetts General Hospital
Boston, Massachusetts

Co-Chair
Karen L. Reckamp, MD, MS

Professor of Medicine
Director
, Division of Medical Oncology
Department of Medicine
Cedars Sinai
Los Angeles, California

Goal Statement
The goal of this program is to improve the knowledge, confidence, and competence of learners in the use of biomarkers to select individualized treatments for patients with NSCLC.

Target Audience
This program is intended for medical oncologists, thoracic oncologists, nurses, pharmacists, and other healthcare professionals who treat and manage patients with non-small-cell lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Assess new and emerging predictive biomarkers to guide precision treatment decisions in patients with NSCLC
  • Discuss the practical aspects of biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, racial disparities, and other nuances
  • Test patients with NSCLC for all appropriate currently available biomarkers to guide treatment selection and clinical trial eligibility
  • Summarize the available data and expert recommendations to determine which biomarkers should be tested in your patients with lung cancer

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. 

UAN live: JA4008176-0000-22-001-L01-P

UAN virtual: JA4008176-0000-22-002-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.